University of California San Francisco, San Francisco, CA
Saya Jacob , Hongmei Yu , Denise M. Wolf , Aheli Chattopadhyay , Susie Brain , Carol Simmons , Kathryn Jean Ruddy , Irene Kang , Anne Hudson Blaes , Amrita B Somani , Dawn L. Hershman , Laura Esserman , Michelle E. Melisko
Background: Patient reported outcomes (PROs) capture direct feedback from patients in clinical trials. The NIH Patient-Reported Outcomes Measurement Information System (PROMIS) is an open source and validated PRO platform. Data on PROMIS score trajectories over time for breast cancer patients undergoing neoadjuvant chemotherapy (NAC) are limited. Methods: We administered paper surveys to patients enrolled on the I-SPY2 trial, a multicenter, randomized phase 2 trial comparing novel agents to standard NAC in high-risk breast cancer. PRO domains included PROMIS Physical Function, Anxiety, Depression, Applied Cognition and Fatigue. Surveys were administered at baseline (post-consent), C1D1, inter-regimen (~12 wks into NAC), pre-surgery and at 1, 6, 12, and 24 months post-surgery. Responses were scored using the HealthMeasures Scoring Service to generate a standardized T score, with a score of 50 representing the general US population mean. Higher Anxiety, Depression and Fatigue scores represent worse symptoms; higher Physical Function and Applied Cognition scores represent better symptoms. We calculated average scores by time-point and compared changes from baseline to various grouped time points using a paired t-test. Results: From 1/2012 to 7/2020, 1631 patients enrolled in I-SPY 2 with 959 completing the baseline survey. 62% had at least two “on-treatment” surveys, and 52% had at least one follow-up time-point. Average baseline PROMIS scores for Physical Function, Anxiety, Depression, Applied Cognition and Fatigue were 46.7, 55.1, 47.2, 53.3 and 46.0 respectively. Between baseline and the latest on-treatment time point we observed improvement in Anxiety (-5.2) and worsening in Physical Function, Applied Cognition and Fatigue (-5.4, -6.9 and +8.2 respectively). Between baseline and the latest post-surgery time point, we saw improved Anxiety (-5.9) and worsened Physical Function, Applied Cognition and Fatigue (-5.9, -3.6 and +4.3). Depression changed minimally. Conclusions: Using PROMIS, patients on I-SPY2 experienced worse Physical Function, Applied Cognition and Fatigue but improved Anxiety during and after treatment compared to baseline. While changes in Applied Cognition and Fatigue recovered partially after treatment, Physical Function scores did not, suggesting potential for longer term impact on quality of life. Clinical trial information: NCT01042379.
Baseline | Cycle 1 | Inter-regimen | Pre-surgery | 1 Mo FU | 6 Mo FU | 12 Mo FU | 24 Mo FU | |
---|---|---|---|---|---|---|---|---|
Completed surveys for those with baseline survey | 959 | 788 | 625 | 499 | 418 | 249 | 214 | 99 |
Physical Function | Anxiety | Depression | Applied Cognition | Fatigue | |
---|---|---|---|---|---|
Change from baseline to latest on-treatment timepoint | ↓5.4 P<0.0001 | ↑5.2 P<0.0001 | ↑0.2 p=0.71 | ↓6.9 P<0.0001 | ↓8.2 P<0.0001 |
Change from baseline to latest post-surgery time point | ↓5.9 P<0.0001 | ↑5.9 P<0.0001 | ↑0.1 p=0.87 | ↓3.6 P<0.0001 | ↓4.3 P<0.0001 |
↑=improved; ↓=worsened.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Natansh Modi
2023 ASCO Annual Meeting
First Author: Kristen E. Champion
2020 ASCO Virtual Scientific Program
First Author: Kevin Nathaniel Johns
2017 ASCO Annual Meeting
First Author: Mark Boye